The realm of cancer chemotherapy is complex and often conflicting. The massive use of cytotoxic agents during the past 25 years has now reached a point where major decisions have to be made. The respective roles of regional techniques, systemic therapy for metastatic disease and adjuvant cytotoxic chemotherapy, all need the most careful re-appraisal. It is important that surgical opinion continues to be expressed and that surgeons continue to participate in the study and practice of cancer chemotherapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jso.2930300411 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Antifungal-drug interactions in oncology: A cross-sectional study highlighting the role of pharmacists.
J Oncol Pharm Pract
January 2025
Department of Pharmacy, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan.
Study Objective: Complex pharmacotherapy in cancer patients increases the likelihood of drug-drug interactions (DDIs). Pharmacists play a critical role in the identification and management of DDIs. The aim of present study was to evaluate the role of pharmacist in identifying antifungal drug interactions in cancer patients and providing relevant recommendations.
View Article and Find Full Text PDFChallenges and adaptations in pancreatic cancer surgery during the COVID-19 pandemic in a high-volume center.
BMC Cancer
January 2025
Department of General, Visceral, and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany.
Background: The COVID-19 pandemic affected healthcare systems worldwide, disrupting elective surgeries including those for cancer treatment. This study examines the effects of the pandemic on outcomes of pancreatic cancer surgeries at a specialized high-volume surgery center.
Materials And Methods: This study compared surgical volume and outcomes of pancreas resections between the pre-pandemic (January 2019 to February 2020), early pandemic (March 2020 to January 2021), and late pandemic (February 2021 to December 2021) periods.
Targeting fucosyltransferase FUT8 as a prospective therapeutic approach for DLBCL.
Oncogenesis
January 2025
Department of Hematology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Diffuse large B-cell lymphoma (DLBCL) is characterized by its aggressive nature and resistance to standard chemotherapy, necessitating the development of new therapeutic approaches. The emergence of natural products and their derivatives has notably influenced cancer treatment, making morusinol, a medicine-derived monomer, a promising candidate. Here, we showed that morusinol exerted antitumor effects on DLBCL in vitro by inducing apoptosis and cell cycle arrest.
View Article and Find Full Text PDFPembrolizumab added to neoadjuvant chemotherapy may improve pathological complete response in androgen-receptor positive and low tumor-infiltrating lymphocytes triple-negative breast cancer patients.
Breast Cancer
January 2025
Tepe Prime, MKA Breast Cancer Clinic, 06800, Ankara, Turkey.
Olaparib-induced hyperglycemia in ovarian cancer patients - a case series analysis of a three-month therapy with a consideration of BMI.
Pharmacol Rep
January 2025
Department of Gynaecological Oncology, Poznań University Clinical Hospital, Szamarzewskiego 84, Poznań, Poland.
Background: Olaparib is a relatively new poly(ADP-ribose) polymerase inhibitor (PARPi) administered to ovarian cancer (OC) patients with a complete or partial response to first-line chemotherapy. One of the metabolic side effects of olaparib is the disruption of glucose homeostasis, often resulting in hyperglycemia The study was a retrospective analysis of olaparib-induced hyperglycemia in OC patients with initial normoglycemia following the first, second, and third month of olaparib treatment METHODS: The study involved 32 OC patients, classified into three groups according to their Body Mass Index (BMI): normal BMI (BMI 18.5-24.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!